Hemoglobin H disease
ICD-10 D56.0 · ICD-11 3A50.02

Treatment of Hemoglobin H Disease: Deletional Form (Three α-Globin Gene Deletion, No Non-Deletional Mutation)

Clinical Scenario

This protocol addresses Haemoglobin H disease in its deletional form — defined by deletion of three α-globin genes with no non-deletional α-globin gene mutation present. Correctly classifying the subtype is essential because the underlying genetic changes largely determine the clinical phenotype and management pathway.

Subtype Characteristics

Deletional HbH disease typically presents as mild, often asymptomatic anaemia. In many patients the diagnosis is unsuspected until an incidental laboratory finding of anaemia prompts a formal diagnostic workup. This milder course distinguishes it from non-deletional forms, which tend to be more clinically significant.

Management Approach (Partial)

First-line management in this setting incorporates targeted nutritional supplementation, initiated at a specific point in early life and adjusted according to monitored levels. The full structured regimen — including which supplements, when to begin, and how to assess response — is available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. Since phenotype is largely determined by underlying genetic changes, it is important to specify the subtype of HbH disease with the terms deletional (deletion of three α-globin genes) and non-deletional (two or three affected α-globin genes, of which one or more have point mutations).
  2. Individuals with deletional HbH disease usually have mild asymptomatic anaemia that remains unsuspected in many cases until an incidental laboratory finding of anaemia prompts diagnostic workup.
  3. Folic acid 0.4 to 1 mg per day is recommended to all patients starting around 6 months.
  4. Vitamin D status is checked to maintain sufficiency, using supplements if needed.
View source ↗